- Home
- RCKY vs ACIU Comparison
RCKY vs ACIU Comparison
Compare RCKY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- ACIU
- Stock Information
- Founded
- RCKY 1932
- ACIU 2003
- Country
- RCKY United States
- ACIU Switzerland
- Employees
- RCKY N/A
- ACIU N/A
- Industry
- RCKY Shoe Manufacturing
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- ACIU Health Care
- Exchange
- RCKY Nasdaq
- ACIU Nasdaq
- Market Cap
- RCKY 205.3M
- ACIU 213.3M
- IPO Year
- RCKY 1993
- ACIU 2016
- Fundamental
- Price
- RCKY $28.98
- ACIU $3.14
- Analyst Decision
- RCKY Buy
- ACIU Strong Buy
- Analyst Count
- RCKY 1
- ACIU 2
- Target Price
- RCKY $40.00
- ACIU $10.00
- AVG Volume (30 Days)
- RCKY 108.0K
- ACIU 360.6K
- Earning Date
- RCKY 10-28-2025
- ACIU 11-04-2025
- Dividend Yield
- RCKY 2.14%
- ACIU N/A
- EPS Growth
- RCKY 53.66
- ACIU N/A
- EPS
- RCKY 2.74
- ACIU N/A
- Revenue
- RCKY $470,314,000.00
- ACIU $5,482,957.00
- Revenue This Year
- RCKY $7.09
- ACIU N/A
- Revenue Next Year
- RCKY $4.27
- ACIU $1,022.98
- P/E Ratio
- RCKY $10.59
- ACIU N/A
- Revenue Growth
- RCKY 4.13
- ACIU N/A
- 52 Week Low
- RCKY $11.93
- ACIU $1.43
- 52 Week High
- RCKY $33.40
- ACIU $4.00
- Technical
- Relative Strength Index (RSI)
- RCKY 50.12
- ACIU 47.43
- Support Level
- RCKY $28.74
- ACIU $3.20
- Resistance Level
- RCKY $31.42
- ACIU $3.42
- Average True Range (ATR)
- RCKY 1.45
- ACIU 0.28
- MACD
- RCKY -0.03
- ACIU -0.05
- Stochastic Oscillator
- RCKY 25.70
- ACIU 14.19
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.